FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4238763583> ?p ?o ?g. }

• W4238763583 endingPage "viii217" @default.
• W4238763583 startingPage "viii216" @default.
• W4238763583 abstract "Background: We initiated the Nationwide Cancer Genome Screening Project in Japan since February 2014. From October 2015, we have introduced the Next Generation Sequencing to detect cancer genome alterations in advanced pancreatic cancer (aPC), called as the SCRUM-Japan GI-SCREEN. Methods: This study is ongoing with 20 major cancer centers. Patients with aPC who plan to or receive chemotherapy were eligible. DNA and RNA were extracted from formalin-fixed paraffin embedded (FFPE) tumor samples and were analyzed by the Oncomine Cancer Research Panel (OCP) which allows to detect mutations, copy number variant (CNV) and fusion genes in a CLIA certified CAP accredited lab. The detected genomic variant data were classified according to genetic drivers of cancer, including gain- and loss-of-function or single nucleotide variant based on the Oncomine Knowledgebase. Results: As of March 31st in 2017, total of 270 aPC patients were enrolled and 209 samples were analyzed. The sequence was successfully performed in 136 tumors (65.1%). The origin of samples included the primary site of 65.4%, metastatic site of 34.6%. The tissue samples were obtained by surgical resection 32.4%, needle biopsy 33.8%, EUS-FNA 27.9%, and other 5.9%. Rate for success sequence of EUS-FNA was 56.7%. The frequently detected mutations (≥ 2%) in 136 samples of which results were available were KRAS (91.9%), TP53 (62.5%), CDKN2A (14.0%), SMAD4 (10.3%), GNAS (4.4%), TET2(4.4%), PIK3CA(3.7%), ATM (2.9%), STK11 (2.9%), BRCA2 (2.2%). Most frequently detected CNVs (≥ 7copies) was MYC (2.9%), and no gene fusion was detected. We will show the clinical outcome based on certain key cancer genome alterations. Conclusions: This nationwide screening system is efficient to detect rare gene alterations in aPC. This novel knowledge provides an intriguing background to investigate new targeted approaches in these patients and to progress precision medicine. Clinical trial identification: UMIN000016344. Legal entity responsible for the study: SCRUM-Japan GI-Screen. Funding: 15 SCRUM-Japan collaborating pharmaceutical companies, AMED, NCC. Disclosure: N. Izawa: Consulting or advisory role: Taiho Pharmaceutical Co., Ltd., Merck Serono Co., Ltd. C. Morizane: Honoraria: Pfizer, Novartis, Yakult Honsha, Eli Lilly Japan K.K, Nobelpharma, Fujifilm, Teijin Pharma, Taiho Pharmaceutical Co., Ltd.; Consulting or advisory role: Yakult Honsha, Novartis, Taiho Pharmaceutical; Research funding (Recipient: my institution): Pfizer, Nobelpharma, Eisai, Yakult Honsha, Ono Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd. H. Takahashi: Honoraria: Taiho Pharmaceutical Co., Ltd.; Research funding: Bayer Pharmaceutical, Bristol-Myers Squibb. M. Ueno: Honoraria: Taiho Pharmaceutical Co., Ltd., Yakult Honsha, AstraZeneca, Novartis, Eli Lilly Japan K.K, Teijin Pharma, Shire, Ono Pharmaceutical Co., Ltd.; Research funding: Taiho Pharmaceutical, Shire, Daiichi Sankyo, Eisai, AstraZeneca, Ono Pharmaceutical Co., Ltd., MSD, Merck Serono Co., Ltd., NanoCarrier, Dainippon Sumitomo Pharma, Incyte. N. Okano: Honoraria: Taiho Pharmaceutical Co., Ltd., Merck Serono Co., Ltd. S. Shimizu: Honoraria: Novartis, Taiho Pharmaceutical Co., Ltd. S. Itoh: Speakers' bureau: Otsuka Pharmaceutical, Asahi Kasei Phama; Consulting or Advisory Role: Asahi Kasei Phama, Takeda; Research funding (Recipient: our institution): Taiho Pharmaceutical Co., Ltd., Sumitomo Dainippon, Daiichi Sankyo, MSD, Yakult Honsha, Chugai Pharmaceutical Co., Ltd, Ono Pharmaceutical Co., Ltd., Astellas, CSL Behring, Novartis, Shionogi, Eli Lilly Japan K.K, Bayer, Merck Serono Co., Ltd., Kyowa Hakko Kirin, Sanofy, Pfizer, Boehringer Ingelheim, Asahi Kasei Phama, Taisho Toyama Pharmaceutical, Kaken Pharmaceutical, Hisamitsu Pharmaceutical, Nihon Pharmaceutical, Nihon Blood Products Organization, Kowa Company, Medtronic, Johnson and Johnson. T. Kudo: Research grants: Yakult Honsha, Chugai Pharmaceutical Co., Ltd, Ono Pharmaceutical Co., Ltd., Bayer Yakuhin, Ltd. S. Nomura: Honoraria: Taiho Pharmaceutical Co., Ltd. T. Kuwata: Honoraria: Chugai Pharmaceutical Co., Ltd, Daiichi-Sankyo Research funding (to institution): Daiichi-Sankyo. W. Okamoto: Grants: MSD. K. Shitara: Consulting or advisory role: Astellas Pharma, Eli Lilly Japan K.K, Bristol-Myers Squibb, Takeda, Pfizer, Ono Pharmaceutical Co., Ltd.; Personal fees: Novartis, AbbVie, Yakult Honsha; Research funding (to institution): Eli Lilly Japan K.K, Ono Pharmaceutical Co., Ltd., Dainippon Sumoitomo Pharma, Daiichi Sankyo, Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd, MSD. A. Ohtsu: Honoraria: Chugai Pharmaceutical Co., Ltd, Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb; Research funding: Bristol-Myers Squibb. T. Yoshino: Grants: MSD K.K., Sumitomo Dainippon Pharma Co., Ltd., GlaxoSmithKline K.K., Nippon Boehringer Ingelheim Co., Ltd, Sanofi K.K., Chugai Pharmaceutical Co., Ltd; Personal fees: Eli Lilly Japan K.K, Merck Serono Co., Ltd, Sanofi K.K., Chugai Pharmaceutical Co., Ltd. All other authors have declared no conflicts of interest." @default.
• W4238763583 created "2022-05-12" @default.
• W4238763583 creator A5001214587 @default.
• W4238763583 creator A5006683327 @default.
• W4238763583 creator A5011235559 @default.
• W4238763583 creator A5014135006 @default.
• W4238763583 creator A5017709438 @default.
• W4238763583 creator A5020198048 @default.
• W4238763583 creator A5024566448 @default.
• W4238763583 creator A5024904484 @default.
• W4238763583 creator A5028473540 @default.
• W4238763583 creator A5029308875 @default.
• W4238763583 creator A5036817380 @default.
• W4238763583 creator A5039647662 @default.
• W4238763583 creator A5046439279 @default.
• W4238763583 creator A5053373925 @default.
• W4238763583 creator A5060246012 @default.
• W4238763583 creator A5060723984 @default.
• W4238763583 creator A5067399580 @default.
• W4238763583 creator A5074627346 @default.
• W4238763583 creator A5077038832 @default.
• W4238763583 creator A5081868383 @default.
• W4238763583 date "2018-10-01" @default.
• W4238763583 modified "2023-10-15" @default.
• W4238763583 title "The nationwide cancer genome screening project in Japan, SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced pancreatic cancer" @default.
• W4238763583 doi "https://doi.org/10.1093/annonc/mdy282.028" @default.
• W4238763583 hasPublicationYear "2018" @default.
• W4238763583 type Work @default.
• W4238763583 citedByCount "2" @default.
• W4238763583 countsByYear W42387635832021 @default.
• W4238763583 countsByYear W42387635832023 @default.
• W4238763583 crossrefType "journal-article" @default.
• W4238763583 hasAuthorship W4238763583A5001214587 @default.
• W4238763583 hasAuthorship W4238763583A5006683327 @default.
• W4238763583 hasAuthorship W4238763583A5011235559 @default.
• W4238763583 hasAuthorship W4238763583A5014135006 @default.
• W4238763583 hasAuthorship W4238763583A5017709438 @default.
• W4238763583 hasAuthorship W4238763583A5020198048 @default.
• W4238763583 hasAuthorship W4238763583A5024566448 @default.
• W4238763583 hasAuthorship W4238763583A5024904484 @default.
• W4238763583 hasAuthorship W4238763583A5028473540 @default.
• W4238763583 hasAuthorship W4238763583A5029308875 @default.
• W4238763583 hasAuthorship W4238763583A5036817380 @default.
• W4238763583 hasAuthorship W4238763583A5039647662 @default.
• W4238763583 hasAuthorship W4238763583A5046439279 @default.
• W4238763583 hasAuthorship W4238763583A5053373925 @default.
• W4238763583 hasAuthorship W4238763583A5060246012 @default.
• W4238763583 hasAuthorship W4238763583A5060723984 @default.
• W4238763583 hasAuthorship W4238763583A5067399580 @default.
• W4238763583 hasAuthorship W4238763583A5074627346 @default.
• W4238763583 hasAuthorship W4238763583A5077038832 @default.
• W4238763583 hasAuthorship W4238763583A5081868383 @default.
• W4238763583 hasBestOaLocation W42387635831 @default.
• W4238763583 hasConcept C1167327 @default.
• W4238763583 hasConcept C121608353 @default.
• W4238763583 hasConcept C126322002 @default.
• W4238763583 hasConcept C143998085 @default.
• W4238763583 hasConcept C2777983448 @default.
• W4238763583 hasConcept C2780210213 @default.
• W4238763583 hasConcept C2780265364 @default.
• W4238763583 hasConcept C2781187634 @default.
• W4238763583 hasConcept C526805850 @default.
• W4238763583 hasConcept C71924100 @default.
• W4238763583 hasConceptScore W4238763583C1167327 @default.
• W4238763583 hasConceptScore W4238763583C121608353 @default.
• W4238763583 hasConceptScore W4238763583C126322002 @default.
• W4238763583 hasConceptScore W4238763583C143998085 @default.
• W4238763583 hasConceptScore W4238763583C2777983448 @default.
• W4238763583 hasConceptScore W4238763583C2780210213 @default.
• W4238763583 hasConceptScore W4238763583C2780265364 @default.
• W4238763583 hasConceptScore W4238763583C2781187634 @default.
• W4238763583 hasConceptScore W4238763583C526805850 @default.
• W4238763583 hasConceptScore W4238763583C71924100 @default.
• W4238763583 hasLocation W42387635831 @default.
• W4238763583 hasOpenAccess W4238763583 @default.
• W4238763583 hasPrimaryLocation W42387635831 @default.
• W4238763583 hasRelatedWork W2035394593 @default.
• W4238763583 hasRelatedWork W2766495528 @default.
• W4238763583 hasRelatedWork W3048477817 @default.
• W4238763583 hasRelatedWork W3138954858 @default.
• W4238763583 hasRelatedWork W3159483703 @default.
• W4238763583 hasRelatedWork W3159941171 @default.
• W4238763583 hasRelatedWork W4233694086 @default.
• W4238763583 hasRelatedWork W4313426539 @default.
• W4238763583 hasRelatedWork W4315707446 @default.
• W4238763583 hasRelatedWork W4383532676 @default.
• W4238763583 hasVolume "29" @default.
• W4238763583 isParatext "false" @default.
• W4238763583 isRetracted "false" @default.
• W4238763583 workType "article" @default.